Alnylam Pharmaceuticals Inc
NASDAQ:ALNY

Watchlist Manager
Alnylam Pharmaceuticals Inc Logo
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Watchlist
Price: 244.74 USD -0.83% Market Closed
Market Cap: 31.6B USD
Have any thoughts about
Alnylam Pharmaceuticals Inc?
Write Note

P/E
Price to Earnings

-94.9
Current
-24.6
Median
22.7
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-94.9
=
Market Cap
31.5B USD
/
Net Income
-332.3m USD
All Countries
Close
Earnings Growth
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Average P/E: 208
Negative Multiple: -94.9
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 080 N/A
US
Abbvie Inc
NYSE:ABBV
61.9
412%
US
Amgen Inc
NASDAQ:AMGN
37.1
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
890.3
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -474.5 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.9 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -130.6 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-128.3
2-Years Forward
P/E
-211.9
3-Years Forward
P/E
93.6

See Also

Discover More